AIM ImmunoTech's Ampligen data accepted for presentation at the SITC Annual Meeting on ovarian cancer research findings.
Quiver AI Summary
AIM ImmunoTech Inc. announced the acceptance of data from a Phase 2 clinical study on cisplatin-resistant advanced recurrent ovarian cancer for presentation at the 40th Annual SITC Meeting, taking place from November 5-9, 2025. The study, which involves the use of their investigational drug Ampligen® (rintatolimod), highlights its potential in combination with locoregional chemoimmunotherapy to trigger T lymphotactic responses correlated with clinical outcomes. The poster presentation will be led by Dr. Mackenzy M. Radolec on November 7, 2025. AIM ImmunoTech focuses on developing therapies for various cancers, immune disorders, and viral diseases. Cautionary statements regarding the forward-looking nature of the release emphasize the inherent risks and uncertainties surrounding the drug's approval and efficacy.
Potential Positives
- Data from a Phase 2 clinical study of Ampligen® was accepted for a late-breaking abstract presentation at a significant medical conference, showcasing the company's research and advancements in cancer treatment.
- The presentation is expected to enhance visibility and credibility within the oncology research community, potentially attracting interest from collaborators and investors.
- AIM ImmunoTech emphasizes its focus on innovative treatments for cancer, immune disorders, and viral diseases, aligning with current trends in the biotech and pharmaceutical industries.
Potential Negatives
- The press release highlights that there are significant risks and uncertainties associated with the development and approval of Ampligen®, which may deter investor confidence.
- It explicitly states that current data and clinical successes do not guarantee future approval of Ampligen®, indicating potential challenges ahead for the company.
- The reliance on forward-looking statements may raise concerns about the company's transparency and the actual progress of its product development.
FAQ
What is the recent announcement from AIM ImmunoTech?
AIM ImmunoTech announced the acceptance of data from their Phase 2 ovarian cancer study at the 40th Annual SITC Meeting.
When and where will the SITC Meeting take place?
The SITC Meeting is scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center, National Harbor, MD.
Who is the presenting author of the AIM study?
The presenting author is Dr. Mackenzy M. Radolec, a Clinical Assistant Professor at UPMC Magee-Women’s Hospital.
What is Ampligen® and its significance in cancer treatment?
Ampligen® (rintatolimod) is AIM's investigational drug designed to treat various cancers, immune disorders, and viral diseases, showcasing broad spectrum activity.
How can I find more information about AIM ImmunoTech?
For more details about AIM ImmunoTech, visit their website at aimimmuno.com and follow them on social media platforms like X, LinkedIn, and Facebook.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIM Insider Trading Activity
$AIM insiders have traded $AIM stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AIM stock by insiders over the last 6 months:
- THOMAS K EQUELS (CEO & President) has made 2 purchases buying 210 shares for an estimated $1,719 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AIM Hedge Fund Activity
We have seen 0 institutional investors add shares of $AIM stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 2,444,319 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,143,359
- BLACKROCK, INC. removed 698,267 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,040,009
- GEODE CAPITAL MANAGEMENT, LLC removed 531,334 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,596,039
- RENAISSANCE TECHNOLOGIES LLC removed 317,979 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,750,518
- STATE STREET CORP removed 173,103 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,497,340
- VERITION FUND MANAGEMENT LLC removed 162,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,401,300
- NORTHERN TRUST CORP removed 85,119 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $736,279
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AIM Analyst Ratings
Wall Street analysts have issued reports on $AIM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 10/03/2025
To track analyst ratings and price targets for $AIM, check out Quiver Quantitative's $AIM forecast page.
Full Release
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen ® (rintatolimod) was accepted in a late-breaking abstract at the 40 th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.
Details of the poster presentation are as follows:
Title:
A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes
Presenting Author:
Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s Hospital
Abstract Number:
1343
Date:
Friday, November 7, 2025
Location:
Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
For more information about the SITC Annual Meeting, please visit sitcancer.org .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen
®
(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit
aimimmuno.com
and connect with the Company on
X
,
LinkedIn
, and
Facebook
.
Cautionary Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
